Newsroom

BOSTON--(BUSINESS WIRE)--Elucid today announced that, effective January 1, 2026, its Plaque-IQ™ coronary plaque analysis has received a new Category I Current Procedural Terminology (CPT®) designation, alongside increasingly widespread coverage and reimbursement from both public and private payors. Together, these developments underscore the clinical value of coronary plaque analysis and establish favorable conditions for broader adoption of the technology. Quantitative coronary plaque analysis...

AUSTIN, Texas--(BUSINESS WIRE)--Sirion, ein weltweit führender Anbieter von Software für das Vertragslebenszyklusmanagement (Contract Lifecycle Management, CLM), gab heute bekannt, dass es eine endgültige Vereinbarung getroffen hat, wonach Haveli Investments, L.P. („Haveli” oder „Haveli Investments”), eine in Austin ansässige, auf Technologie spezialisierte Investmentgesellschaft, eine Mehrheitsbeteiligung an dem Unternehmen erwerben wird. Sirion unterstützt einige der weltweit größten Unterneh...

DUBLIN--(BUSINESS WIRE)--The "Aircraft Avionics MRO Market Size, Share, Trends, Dynamics, Forecast, & Growth Analysis: 2025-2035" report has been added to ResearchAndMarkets.com's offering. The aircraft avionics MRO market size was valued at US$7.1 billion in 2024 and is expected to reach US$10.3 billion by 2035, growing at a CAGR of 3.8% during the forecast period. The aircraft avionics MRO market is experiencing strong growth, fueled by multiple factors reshaping the aviation industry. Ri...

BEIJING & ALAMEDA, Calif. & TAIPEI, Taiwan--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to ob...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--GC Therapeutics, Inc. (GCTx), a biotechnology company created to scale and unlock the next generation of cell therapy-based medicines through its TFome™ cellular programming platform, today announced a series of corporate and pipeline updates. GCTx unveiled its initial pipeline programs focused on demyelinating neurological disorders, including multiple sclerosis (MS), and a regenerative cell therapy program for metabolic diseases, including Type 1 Diabetes. B...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discovery and development by providing access to advanced artificial intelligence (AI) capabilities. TuneLab will be made available in LiveDesign, Schrödinger’s widely used enterprise informatics platform, as a priority interface for participating biotech companies to access TuneLab workflows. “As a lead...

HANAU, Germany--(BUSINESS WIRE)--The Bruker Energy & Supercon Technologies (BEST) division, a segment of Bruker Corporation (Nasdaq: BRKR), today announced two multi-year supply agreements for Bruker’s latest superconductors, which are used by global radiology companies to build their next generations of magnetic resonance imaging (MRI) magnets. The combined order value of the two agreements is approximately $500 million in expected future BEST revenues, with different agreement duration pe...

COLUMBUS, Ohio--(BUSINESS WIRE)--Clarametyx today announced positive topline data from a Phase 1b/2a trial evaluating its novel antibody therapy, CMTX-101, in cystic fibrosis (CF)....

GOLDEN, Colo. & MONTREAL--(BUSINESS WIRE)--MOLSON COORS BEVERAGE COMPANY ANNOUNCES 2025 FOURTH QUARTER AND FULL YEAR EARNINGS DATE AND PARTICIPATION AT THE 2026 CAGNY CONFERENCE...

BEIJING & ALAMEDA, Calif. & TAIPEI--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an...